Mayinglong Pharmaceutical Group Co Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mayinglong Pharmaceutical Group Co Ltd with three other
companies in this sector in China:
Shanghai Dingli Technology Development (Group) Co.Ltd
sales of 1.71 billion Chinese Renmimbi [US$248.47 million]
of which 83%
Zhangzhou Pientzehuang Pharmaceutical Company Ltd
(1.88 billion Chinese Renmimbi [US$273.11 million]
SSY Group Ltd
(1.80 billion Chinese Renmimbi [US$261.18 million]
of which 98%
was Intravenous Infusion Solution and Others).
Mayinglong Pharmaceutical Group Co Ltd reported sales of 1.78 billion Chinese Renmimbi (US$258.33 million)
December of 2015.
increase of 10.1%
versus 2014, when the company's sales were 1.62 billion Chinese Renmimbi.
Sales at Mayinglong Pharmaceutical Group Co Ltd have increased during each of the previous five years
(and since 2010, sales have increased a total of 51%).
Sales of the Hospital Diagnosis and Treatment saw an increase
that was more than double the company's growth rate: sales were up
50.1% in 2015, from
78.07 million Chinese Renmimbi to 117.21 million Chinese Renmimbi.